Form 4: iBio Director David Arkowitz Reports Purchase of 18,382 Shares
SEC Form 4
Director David Arkowitz reports purchasing 18,382 shares of iBio, Inc. at $2.72 per share on January 10, 2025.
Summary
- On January 10, 2025, David Arkowitz, a director of iBio, Inc., purchased 18,382 shares of common stock.
- The purchase was made at a price of $2.72 per share.
- The transaction was conducted pursuant to a Securities Purchase Agreement with iBio, Inc.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. An insider purchase is generally viewed favorably, but the impact depends on the size of the purchase relative to the insider's holdings and the overall market capitalization of the company.
Positives
- A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders. This purchase could be seen as a positive signal, but should be considered in the context of overall market conditions and company performance.
Stakeholder Impact
- Shareholders may view the director's purchase as a positive sign of confidence in the company's prospects.
Key Dates
| Date | Description |
|---|---|
| 01/10/2025 | Date of transaction: David Arkowitz purchased shares of iBio, Inc. |
| 01/10/2025 | Date of Securities Purchase Agreement with iBio, Inc. |
| 01/13/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.